gp130 blockade to NOD off Crohn's disease.

Mukherjee, Tapas; Philpott, Dana J

Mukherjee, Tapas; Philpott, Dana J.

Afiliación

Mukherjee T; Department of Immunology, Medical Sciences Building, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
Philpott DJ; Department of Immunology, Medical Sciences Building, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada. Electronic address: dana.philpott@utoronto.ca.

Trends Immunol ; 42(7): 551-553, 2021 07.

Article en En | MEDLINE | ID: mdl-34103266

ABSTRACT

ABSTRACT

In a recent publication, Nayar et al. uncover specific inflammatory cell populations associated with Crohn's disease (CD) pathogenesis, and a gp130-STAT3 signaling axis linked to disease in anti-TNF antibody treatment-refractory patients. Therefore, gp130 blockade might represent a potential CD therapy approach, perhaps in conjunction with existing anti-TNF treatment regimes.

Asunto(s)

Enfermedad de Crohn; Receptor gp130 de Citocinas; Humanos; Infliximab; Inhibidores del Factor de Necrosis Tumoral; Factor de Necrosis Tumoral alfa

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Crohn Límite: Humans Idioma: En Revista: Trends Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google